Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

PBE vs BIB overlap: 31% of top holdings shared

Bottom line

How much do PBE and BIB overlap?

31% of their top holdings overlap by weight. 9 securities appear in both funds' top 25, making up 38.7% of PBE's assets and 23.9% of BIB's. They share a meaningful core but differ in the rest of the portfolio.

BIB holds far more positions (267 vs 33), so it is broader beyond the top names.

Updated Nov 22, 2026

Overlap at a glance

PBEBIB
Weight overlap (top 25)31%
Shared holdings9
Weight in shared holdings38.7%23.9%
Total positions33267
Expense ratio0.59%0.95%
Holdings as ofJul 31, 2026May 31, 2026

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Holdings PBE and BIB have in common

Holding% of PBE% of BIBOverlap
Regeneron Pharmaceuticals, Inc.5.47%3.21%3.21%
Amgen Inc.5.22%4.48%4.48%
Vertex Pharmaceuticals Inc.4.99%4.65%4.65%
Biogen Inc.4.79%1.44%1.44%
Gilead Sciences, Inc.4.43%4.66%4.43%
United Therapeutics Corp.4.08%1.22%1.22%
Illumina, Inc.3.51%1.25%1.25%
Alnylam Pharmaceuticals, Inc.3.17%2.01%2.01%
Incyte Corp.3.06%0.97%0.97%

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in PBE

  1. Invesco Private Prime Fund — 12.89%
  2. CareDx, Inc. — 5.04%
  3. Invesco Private Government Fund — 4.97%
  4. Royalty Pharma PLC — 4.94%
  5. Bio-Techne Corp. — 3.73%
  6. Protagonist Therapeutics, Inc. — 3.40%
  7. Vericel Corp. — 3.27%
  8. Repligen Corp. — 3.04%
  9. Acadia Pharmaceuticals Inc. — 3.02%
  10. Halozyme Therapeutics, Inc. — 2.98%
  11. Qiagen N.V. — 2.89%
  12. BioMarin Pharmaceutical Inc. — 2.82%
  13. Neurocrine Biosciences, Inc. — 2.66%
  14. Exelixis, Inc. — 2.64%
  15. BioCryst Pharmaceuticals, Inc. — 2.63%

Only in BIB

  1. N/a — 7.35%
  2. ProShares GENIUS Money Market ETF — 6.80%
  3. N/a — 3.94%
  4. N/a — 3.26%
  5. N/a — 2.62%
  6. Revolution Medicines, Inc. — 1.57%
  7. Repurchase Agreement — 1.28%
  8. Royalty Pharma plc — 1.20%
  9. Argenx SE — 1.19%
  10. N/a — 1.18%
  11. Insmed, Inc. — 1.16%
  12. Roivant Sciences Ltd. — 1.08%
  13. Viatris, Inc. — 0.94%
  14. Moderna, Inc. — 0.94%
  15. Guardant Health, Inc. — 0.85%

Asset mix

Asset typePBEBIB
Stocks100.1%63.0%
Cash & short-term funds17.9%0.8%
Equity derivatives—16.0%
Other—6.8%
Repurchase agreements—3.1%

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Country mix

CountryPBEBIB
US108.6%79.8%
GB4.9%1.7%
NL2.9%1.6%
KY1.6%0.4%
IE—1.2%
BM—1.1%
FR—1.0%
DK—0.8%

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Check another pair

FAQ

How much do PBE and BIB overlap?
About 31% by weight. 9 securities appear in both funds' top 25 holdings; they make up 38.7% of PBE's assets and 23.9% of BIB's. They share a meaningful core but differ in the rest of the portfolio.
What stocks do PBE and BIB have in common?
The largest shared holdings are Vertex Pharmaceuticals Inc., Amgen Inc., Gilead Sciences, Inc., Regeneron Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc..
Should I own both PBE and BIB?
They overlap in part. Owning both concentrates you in the shared names; check that the combined weight in those stocks is what you intend.
Which holds more stocks, PBE or BIB?
BIB is broader, with 267 positions versus 33 for PBE. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.